{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:18:26Z","timestamp":1768522706146,"version":"3.49.0"},"posted":{"date-parts":[[2025,5,9]]},"group-title":"Microbiology","reference-count":30,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  The fungal pathogen\n                  <jats:italic>Candida auris<\/jats:italic>\n                  is of global concern due to high levels of multidrug resistance and its propensity to cause infectious outbreaks. Over 90% of isolates are resistant to fluconazole, the most commonly prescribed antifungal world-wide. Fluconazole resistance is multifactorial with many isolates carrying mutations in the gene encoding the transcriptional regulator Tac1B, leading to increased expression of the gene encoding the ATP Binding Cassette (ABC) transporter Cdr1. Recently, a study examining\n                  <jats:italic>C. auris<\/jats:italic>\n                  in vitro resistance mechanisms to manogepix, a promising antifungal agent currently in clinical trials, found a\n                  <jats:italic>TAC1B<\/jats:italic>\n                  mutation that confers reduced manogepix and fluconazole susceptibility. We hypothesized that mutations in\n                  <jats:italic>C. auris TAC1B<\/jats:italic>\n                  and similar transcription factors in other\n                  <jats:italic>Candida<\/jats:italic>\n                  species that confer fluconazole resistance might also confer reduced susceptibility to manogepix. We measured manogepix susceptibilities for selected isolates and strains and found\n                  <jats:italic>C. auris TAC1B<\/jats:italic>\n                  ,\n                  <jats:italic>C. albicans<\/jats:italic>\n                  and\n                  <jats:italic>C. parapsilosis TAC1<\/jats:italic>\n                  , and\n                  <jats:italic>C. glabrata PDR1<\/jats:italic>\n                  confer reduced manogepix susceptibility in a manner dependent on ABC transporters similar to Cdr1. Our findings raise the possibility of fluconazole and manogepix cross resistance for clinical isolates harboring mutations in these genes.\n                <\/jats:p>","DOI":"10.1101\/2025.05.07.652603","type":"posted-content","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:10:15Z","timestamp":1746789015000},"source":"Crossref","is-referenced-by-count":0,"title":["Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in\n                  <i>Candida auris<\/i>\n                  ,\n                  <i>Candida albicans<\/i>\n                  ,\n                  <i>Candida parapsilosis<\/i>\n                  , and\n                  <i>Candida glabrata<\/i>\n                  (\n                  <i>Nakaseomyces glabratus<\/i>\n                  )"],"prefix":"10.64898","author":[{"given":"Katherine S.","family":"Barker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoja P.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-8687","authenticated-orcid":false,"given":"Joachim","family":"Morschh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-960X","authenticated-orcid":false,"given":"Christina A.","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":false,"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0679","authenticated-orcid":false,"given":"P. David","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025051302050947000_2025.05.07.652603v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00692-8"},{"key":"2025051302050947000_2025.05.07.652603v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"2025051302050947000_2025.05.07.652603v1.3","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3469"},{"key":"2025051302050947000_2025.05.07.652603v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00960-9"},{"key":"2025051302050947000_2025.05.07.652603v1.5","first-page":"e68","article-title":"Outpatient Antifungal Prescribing Patterns in the United States, 2018","volume":"1","year":"2022","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2025051302050947000_2025.05.07.652603v1.6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1070"},{"key":"2025051302050947000_2025.05.07.652603v1.7","first-page":"e00429","article-title":"Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs","volume":"64","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051302050947000_2025.05.07.652603v1.8","first-page":"e01225","article-title":"APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method","volume":"62","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051302050947000_2025.05.07.652603v1.9","first-page":"e00261","article-title":"Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility","volume":"64","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051302050947000_2025.05.07.652603v1.10","doi-asserted-by":"publisher","DOI":"10.1128\/EC.3.6.1639-1652.2004"},{"key":"2025051302050947000_2025.05.07.652603v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.07.005"},{"key":"2025051302050947000_2025.05.07.652603v1.12","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00365-20"},{"key":"2025051302050947000_2025.05.07.652603v1.13","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.11.637698"},{"key":"2025051302050947000_2025.05.07.652603v1.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2008.06143.x"},{"key":"2025051302050947000_2025.05.07.652603v1.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2006.05235.x"},{"key":"2025051302050947000_2025.05.07.652603v1.16","first-page":"e01070","article-title":"Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata","volume":"62","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051302050947000_2025.05.07.652603v1.17","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01508-24"},{"key":"2025051302050947000_2025.05.07.652603v1.18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00498.x"},{"key":"2025051302050947000_2025.05.07.652603v1.19","first-page":"e00584","article-title":"Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051302050947000_2025.05.07.652603v1.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2378"},{"key":"2025051302050947000_2025.05.07.652603v1.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1482"},{"key":"2025051302050947000_2025.05.07.652603v1.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2007.05931.x"},{"key":"2025051302050947000_2025.05.07.652603v1.23","doi-asserted-by":"publisher","DOI":"10.1128\/EC.00073-10"},{"key":"2025051302050947000_2025.05.07.652603v1.24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad256"},{"key":"2025051302050947000_2025.05.07.652603v1.25","unstructured":"CLSI. 2017. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI Standard M27. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania."},{"key":"2025051302050947000_2025.05.07.652603v1.26","unstructured":"CLSI. 2022. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 3rd Ed. CLSI supplement M27M44S. Clinical and Laboratory Standards Institute."},{"key":"2025051302050947000_2025.05.07.652603v1.27","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13022"},{"key":"2025051302050947000_2025.05.07.652603v1.28","doi-asserted-by":"publisher","DOI":"10.1007\/BF00328721"},{"key":"2025051302050947000_2025.05.07.652603v1.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01358-15"},{"key":"2025051302050947000_2025.05.07.652603v1.30","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.529-535.2006"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.05.07.652603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:39:49Z","timestamp":1768466389000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.05.07.652603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1101\/2025.05.07.652603","relation":{},"subject":[],"published":{"date-parts":[[2025,5,9]]},"subtype":"preprint"}}